Sl No Brand Q1 H1 9M Total 1 Johnson and Johnson $24.1 $49.4 2 Eli Lilly $19.8 3 Roche $18.8 4 AstraZeneca $15.3 5 Novo Nordisk $15.2 6 AbbVie $15.0 7 Pfizer $14.4 8 Merck $14.3 9 Novartis $13.1 10 Sanofi $12.4 The first quarter of 2026 confirmed that GLP-1 drugs are still rewriting the global pharmaceutical revenue rankings. Eli Lilly posted $19.8 billion revenues, the fastest rate among the top 10 companies, driven entirely by Mounjaro and Zepbound demand. Johnson and Johns

Top 10 healthcare companies by revenues | 2026 Rank Company Q1 H1 9M 2026 revenues 1 United Health Group $111.7 $223.7 2 CVS Health $100.4 3 Cigna Group $68.5 4 Centene $49.9 5 Elevance Health $49.5 6 Humana $39.6 7 Kaiser Permanente $34.6 8 HCA Healthcare $19.1 9 HCSC $16.6 10 Molina Healthcare $10.8 Top Healthcare Companies by Revenues | 2026 United Health Group Q1 REVENUES: UnitedHealth Group reported first-quarter 2026 revenues of $111.7 billion, representing a 2% increa

The Central Drugs Standard Control Organisation (CDSCO) has officially authorized the marketing of Qdenga, a dengue tetravalent vaccine manufactured by Takeda, marking a significant development in India’s public health strategy. The approval introduces the first preventative immunologic tool against dengue fever in the country. This regulatory milestone follows a comprehensive evaluation of the vaccine’s safety, quality, and efficacy under the provisions of the Drugs and Cosm

On July 16, 2026, the Centers for Medicare & Medicaid Services (CMS) issued a new draft guidance that fills in critical operational details for the Inflation Reduction Act’s drug price negotiation program. The document explains how pharmaceutical manufacturers will be expected to implement Medicare’s negotiated prices when they go live in 2028, with specific expectations for both pharmacy-dispensed and physician-administered therapies. For life sciences companies, this guidan

The Centers for Medicare & Medicaid Services (CMS) has unveiled a comprehensive, three-pillar strategy aimed at fundamentally restructuring Original Medicare (OM) by transitioning away from traditional, fragmented fee-for-service payment models. The new framework seeks to optimize spending efficiency, expand patient-centric decision-making, and strengthen provider accountability within the Medicare Shared Savings Program. This initiative reflects the agency’s intensified focu

Takeda Reports Positive Phase 3 Results for Zasocitinib in Plaque Psoriasis Takeda Pharmaceutical has announced positive results from its pivotal Phase 3 LATITUDE PsO 3001 and 3002 clinical trials, establishing its selective TYK2 inhibitor, zasocitinib, as a high-efficacy oral candidate for moderate-to-severe plaque psoriasis. With approximately 70 percent of participants achieving a static Physician Global Assessment (sPGA) score of clear or almost clear by the 16-week mark,

Eli Lilly and Company has announced a definitive agreement to acquire clinical-stage biopharmaceutical firm AtaiBeckley in a transaction valued at up to $3.8 billion. The acquisition aims to significantly expand Lilly’s neuroscience pipeline by integrating advanced neuroplastogen therapies designed to treat complex and treatment-resistant mental health conditions. Key Regulatory Proposals The financial terms of the agreement include an initial $2.8 billion upfront cash paymen

The European Commission has issued marketing authorization for once-daily oral semaglutide 25 mg tablets, marketed under the Wegovy brand, for the management of obesity and weight-associated comorbidities in adults. This regulatory milestone marks the introduction of the first GLP-1 receptor agonist in oral form for weight management within the European Union, extending the drug’s existing presence in the United States, the United Kingdom, the United Arab Emirates, and Bahra

Key Regulatory Proposals Aetna, a CVS Health company, has released the results of its second quarterly Provider Survey, highlighting a notable shift in the relationship between healthcare payers and providers. According to the data, the average provider trust score for payers has increased to 6.1, up from 5.4 in the first quarter of the year. Approximately 38% of survey participants now rate their payer partners an 8 or higher on a 10-point scale. Operational improvements app

The U.S. Food and Drug Administration (FDA) has approved Celcuity’s REVTORPYK (gedatolisib) for the treatment of HR+/HER2- metastatic breast cancer patients who do not possess a PIK3CA mutation. As the first therapy capable of inhibiting all class I PI3K isoforms (α, β, δ, γ) in conjunction with both mTORC1 and mTORC2 complexes, REVTORPYK introduces a novel mechanism of action for a patient population that accounts for approximately 42% of all HR+/HER2- diagnoses. Also read:

The Centers for Medicare & Medicaid Services (CMS) has introduced a broad regulatory proposal aimed at restructuring Medicare physician payments and accelerating the transition toward value-based care. The initiative centers on four strategic objectives: Broadening participation in accountable care models Refining payment methodologies Streamlining administrative operations Prioritizing proactive preventative medicine over traditional reactive healthcare delivery Key Regulato

The German Bundestag has officially ratified new legislation designed to stabilize the nation’s statutory health insurance (SHI) framework by imposing rigorous expenditure controls across the hospital and pharmaceutical sectors. The mandate enforces strict limitations on hospital spending growth, tied to the basic wage rate minus one percentage point through 2029, while simultaneously shifting regulatory focus toward administrative efficiency and service quality oversight. Al

AstraZeneca has finalized an agreement to acquire global rights to Zegfrovy (sunvozertinib), a targeted, irreversible EGFR inhibitor developed by Dizal Pharmaceutical. This strategic expansion is designed to solidify AstraZeneca’s position in the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients specifically harboring EGFR exon 20 insertion mutations. Efficacy of Zegfrovy as first-line therapy in NSCLC patients with EGFR Exon 20 Insertion

The U.S. Food and Drug Administration (FDA) has officially approved the subcutaneous formulation of Sarclisa (isatuximab), branded as Escena, establishing it as the first anticancer therapy to utilize an on-body injector (OBI). Also read: CVS Pharmacy Joins Medicare GLP-1 Bridge and Scales Weight‑Loss Access Across the U.S Powered by the CirCLIQ platform, this new delivery method offers patients the option for either manual subcutaneous administration or automated, hands-free

A major transition is underway in the U.S. pharmacy benefit sector as corporate employers increasingly abandon traditional rebate-based structures in favor of transparent, fee-only models. Recent data from the Penta Group indicates that nearly 90% of U.S. employers are now actively seeking pharmacy benefit management (PBM) agreements that bypass legacy rebate systems to ensure that negotiated drug savings are passed directly to plan members. Also read: CVS Pharmacy Joins Medi